This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser.
SEC.gov
EDGAR
Latest Filings
Filings search tools
Filing Detail
SEC Home
»
Company Search
»
Current Page
Form C
- Offering Statement:
SEC
Accession
No.
0001670254-21-000639
Filing Date
2021-05-05
Accepted
2021-05-04 20:12:06
Documents
13
Document Format Files
Seq
Description
Document
Type
Size
1
primary_doc.html
C
1
primary_doc.xml
C
11762
2
document_1.pdf
EX-99
7327921
3
document_2.pdf
EX-99
2141695
4
document_3.pdf
EX-99
19252025
5
document_4.pdf
EX-99
19252025
6
document_5.pdf
EX-99
9302341
7
document_6.pdf
EX-99
9302255
8
document_7.pdf
EX-99
10892744
9
document_8.pdf
EX-99
822417
10
document_9.pdf
EX-99
3829629
11
document_10.pdf
EX-99
524358
12
document_11.pdf
EX-99
877730
13
documents_list.htm
EX-99
123
Complete submission text file
0001670254-21-000639.txt
113098452
Mailing Address
2145 S CLERMONT ST STE 3
DENVER
CO
80222
Business Address
2145 S CLERMONT ST STE 3
DENVER
CO
80222
5106982462
Canine Life Sciences Inc. (Filer)
CIK
:
0001857342 (see all company filings)
EIN.
:
844068759
Type:
C
| Act:
33
| File No.:
020-28031
| Film No.:
21890677